IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
38.41
-0.20 (-0.52%)
At close: Sep 18, 2026, 4:00 PM EDT
37.00
-1.41 (-3.67%)
After-hours: Sep 18, 2026, 7:30 PM EDT
IDEAYA Biosciences Employees
IDEAYA Biosciences had 145 employees as of December 31, 2025. The number of employees increased by 14 or 10.69% compared to the previous year.
Employees
145
Change (1Y)
14
Growth (1Y)
10.69%
Revenue / Employee
$1,614,669
Profits / Employee
-$1,207,034
Market Cap
3.71B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 145 | 14 | 10.69% | 145 | 0 |
| Dec 31, 2024 | 131 | 7 | 5.65% | 131 | 0 |
| Dec 31, 2023 | 124 | 21 | 20.39% | 124 | 0 |
| Sep 30, 2023 | 122 | 27 | 28.42% | 122 | 0 |
| Jun 30, 2023 | 116 | 25 | 27.47% | 116 | 0 |
| Mar 31, 2023 | 107 | 20 | 22.99% | 107 | 0 |
| Dec 31, 2022 | 103 | 22 | 27.16% | 103 | 0 |
| Sep 30, 2022 | 95 | 12 | 14.46% | 95 | 0 |
| Jun 30, 2022 | 91 | 16 | 21.33% | 91 | 0 |
| Mar 31, 2022 | 87 | 18 | 26.09% | 87 | 0 |
| Dec 31, 2021 | 81 | 19 | 30.65% | 81 | 0 |
| Sep 30, 2021 | 83 | 25 | 43.10% | 83 | 0 |
| Jun 30, 2021 | 75 | 29 | 63.04% | 75 | 0 |
| Mar 31, 2021 | 69 | 26 | 60.47% | 69 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Arcus Biosciences | 601 |
| AbCellera Biologics | 562 |
| Xenon Pharmaceuticals | 370 |
| Tarsus Pharmaceuticals | 370 |
| Dyne Therapeutics | 289 |
| Relay Therapeutics | 202 |
| Celcuity | 155 |
IDYA News
- 5 days ago - IDEAYA Biosciences Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 9 days ago - IDEAYA Biosciences Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts
- 10 days ago - IDEAYA Biosciences Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 10 days ago - Ideaya Biosciences price target raised to $57 from $54 at Guggenheim - TheFly
- 10 days ago - Ideaya Biosciences doses first patient in OptimUM-11 trial - TheFly
- 10 days ago - IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma - PRNewsWire
- 11 days ago - IDEAYA Biosciences Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 18 days ago - IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences - PRNewsWire